利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

36 条记录 (耗时 0.037 秒)

    Antibiotic AM-3603
    2.
    发明授权
    Antibiotic AM-3603 失效
    抗生素AM-3603

    公开(公告)号：US4493845A

    公开(公告)日：1985-01-15

    申请号：US434818

    申请日：1982-10-18

    申请人： Satoshi Omura ,  Yoshitake Tanaka ,  Yuzuru Iwai ,  Yoko Takahashi ,  Akira Nakagawa

    发明人： Satoshi Omura ,  Yoshitake Tanaka ,  Yuzuru Iwai ,  Yoko Takahashi ,  Akira Nakagawa

    IPC分类号： C07H17/08 ,  A61K31/325 ,  A61K31/35 ,  A61K35/74 ,  A61P31/04 ,  C07G11/00 ,  C12P1/06 ,  C12P17/18 ,  C07D491/08

    CPC分类号： C12R1/465 ,  C12P1/06

    摘要： Antibiotic AM-3603 which is also designated as irumamycin is represented by the following formula: ##STR1## This substance is active upon certain Gram-positive bacteria, phytopathogenic fungi and dermatophytes, and is of interest in treating various diseases of humans and animals caused by infectious bacteria and fungi and also useful for agricultural purposes. Antibiotic AM-3603 may be prepared by fermentation, in which a microorganism capable of producing AM-3603 is cultured in a medium to accumulate AM-3603 in the cultured broths, from which AM-3603 is recovered. A preferred strain is Streptomyces sp. AM-3603 (FERM-P 5619; NRRL 12518).

    摘要翻译： 也被称为伊马利霉素的抗生素AM-3603由下式表示：该物质对某些革兰氏阳性菌，植物病原真菌和皮肤癣菌有活性，并且对于治疗人类和动物引起的各种疾病感兴趣 感染性细菌和真菌，也可用于农业目的。 抗生素AM-3603可以通过发酵制备，其中能够产生AM-3603的微生物在培养基中培养以在收集AM-3603的培养肉汤中积累AM-3603。 优选的菌株是链霉菌属（Streptomyces sp。）。 AM-3603（FERM-P 5619; NRRL 12518）。

    Novel K04-0144 Substance and a Process for Production Thereof
    3.
    发明申请
    Novel K04-0144 Substance and a Process for Production Thereof 有权
    新型K04-0144物质及其生产工艺

    公开(公告)号：US20090130717A1

    公开(公告)日：2009-05-21

    申请号：US12084878

    申请日：2006-05-16

    申请人： Satoshi Omura ,  Hiroshi Tomoda ,  Yong-pil Kim ,  Hideaki Hanaki ,  Atsuko Matsumoto ,  Yoko Takahashi

    发明人： Satoshi Omura ,  Hiroshi Tomoda ,  Yong-pil Kim ,  Hideaki Hanaki ,  Atsuko Matsumoto ,  Yoko Takahashi

    IPC分类号： C12P19/44 ,  C07H15/10 ,  C12P13/02 ,  C12N1/20 ,  C07C59/62

    CPC分类号： C07H11/04 ,  C07C323/59 ,  C12P13/02 ,  C12P19/26 ,  C12P19/44 ,  C12R1/465

    摘要： A microorganism represented by a strain K04-0144 belonging to Streptomyces sp. having ability to produce K04-0144 substance is cultured in the medium, and the isolated K04-0144A substance, K04-0144B substance and K04-0144C substance therefrom have strong antibacterial activities against Gram-positive bacteria including methicillin-resistant Streptococcus aureus (MRSA), consequently these are useful as the therapeutic agents for infectious disease caused by MRSA as well as infectious diseases caused by multidrug including β-lactam antibiotics resistant bacteria. Further, similarly, since the novel K04-0144D substance isolated from the cultured liquid has the action for enhancing the effect of β-lactam antibiotics, which are utilized as the antibacterial agents, in combination with them, it is useful as the therapeutic agent for infectious diseases caused by methicillin-resistant Staphylococcus aureus (MRSA) and multidrug including β-lactam antibiotics resistant bacteria.

    摘要翻译： 属于Streptomyces sp。的菌株K04-0144所代表的微生物 在培养基中培养生产K04-0144物质的能力，分离的K04-0144A物质，K04-0144B物质和K04-0144C物质对革兰氏阳性菌（包括耐甲氧西林金黄色葡萄球菌（MRSA））具有很强的抗菌活性， 因此，这些可用作由MRSA引起的感染性疾病的治疗剂以及由多种药物（包括β-内酰胺抗生素抗性细菌）引起的感染性疾病。 此外，类似地，由于从培养液体中分离的新型K04-0144D物质具有增强作为抗菌剂的β-内酰胺抗生素与其组合的作用，因此可用作治疗剂 由耐甲氧西林金黄色葡萄球菌（MRSA）引起的感染性疾病和包括β-内酰胺抗生素抗性细菌在内的多种药物。

    Novel substances k01-b0171 and process for producing the same
    5.
    发明申请
    Novel substances k01-b0171 and process for producing the same 失效
    新型物质k01-b0171及其制造方法

    公开(公告)号：US20060089298A1

    公开(公告)日：2006-04-27

    申请号：US10508413

    申请日：2003-01-17

    申请人： Satoshi Omura ,  Hiroshi Tomoda ,  Masato Iwatsuki ,  Yoko Takahashi

    发明人： Satoshi Omura ,  Hiroshi Tomoda ,  Masato Iwatsuki ,  Yoko Takahashi

    IPC分类号： A61K38/12 ,  C07K7/64 ,  C12P21/06 ,  C12N1/20

    CPC分类号： C07K7/56 ,  A61K38/00 ,  C07K7/02 ,  C07K7/60

    摘要： The present invention is comprised of culturing a microorganism having ability to produce K01-B0171-B substance and/or K01-B0171-C substance in a medium, accumulating K01-B0171-B substance and/or K01-B0171-C substance in a culture fluid and isolating K01-B0171-B substance and/or, K01-B0171-C substance from the culture fluid. The obtained K01-B0171-B substance, K01-B0171-C substance or a composition of these substances is expected to be useful as a medicament of antituberculous agent.

    摘要翻译： 本发明包括在培养基中培养具有生产K01-B0171-B物质和/或K01-B0171-C物质的微生物的微生物，将K01-B0171-B物质和/或K01-B0171-C物质累积在 培养液并从培养液中分离K01-B0171-B物质和/或K01-B0171-C物质。 获得的K01-B0171-B物质，K01-B0171-C物质或这些物质的组合物预期可用作抗结核药物的药物。

    Substances K01-B0171 and process for producing the same
    7.
    发明授权
    Substances K01-B0171 and process for producing the same 失效
    物质K01-B0171及其制造方法

    公开(公告)号：US07439225B2

    公开(公告)日：2008-10-21

    申请号：US10508413

    申请日：2003-01-17

    申请人： Satoshi Omura ,  Hiroshi Tomoda ,  Masato Iwatsuki ,  Yoko Takahashi

    发明人： Satoshi Omura ,  Hiroshi Tomoda ,  Masato Iwatsuki ,  Yoko Takahashi

    IPC分类号： A61K38/12

    CPC分类号： C07K7/56 ,  A61K38/00 ,  C07K7/02 ,  C07K7/60

    摘要： The present invention is comprised of culturing a microorganism having ability to produce K01-B0171-B substance and/or K01-B0171-C substance in a medium, accumulating K01-B0171-B substance and/or K01-B0171-C substance in a culture fluid and isolating K01-B0171-B substance and/or, K01-B0171-C substance from the culture fluid. The obtained K01-B0171-B substance, K01-B0171-C substance or a composition of these substances is expected to be useful as a medicament of antituberculous agent.

    摘要翻译： 本发明包括在培养基中培养具有生产K01-B0171-B物质和/或K01-B0171-C物质的微生物的微生物，将K01-B0171-B物质和/或K01-B0171-C物质累积在 培养液并从培养液中分离K01-B0171-B物质和/或K01-B0171-C物质。 获得的K01-B0171-B物质，K01-B0171-C物质或这些物质的组合物预期可用作抗结核药物的药物。

    K04-0144 substance and a process for production thereof
    9.
    发明授权
    K04-0144 substance and a process for production thereof 有权
    K04-0144物质及其生产方法

    公开(公告)号：US07973147B2

    公开(公告)日：2011-07-05

    申请号：US12084878

    申请日：2006-05-16

    申请人： Satoshi Omura ,  Hiroshi Tomoda ,  Yong-pil Kim ,  Hideaki Hanaki ,  Atsuko Matsumoto ,  Yoko Takahashi

    发明人： Satoshi Omura ,  Hiroshi Tomoda ,  Yong-pil Kim ,  Hideaki Hanaki ,  Atsuko Matsumoto ,  Yoko Takahashi

    IPC分类号： C07H15/20 ,  C07H15/22 ,  C07C61/12

    CPC分类号： C07H11/04 ,  C07C323/59 ,  C12P13/02 ,  C12P19/26 ,  C12P19/44 ,  C12R1/465

    摘要： A microorganism represented by a strain K04-0144 belonging to Streptomyces sp. having ability to produce K04-0144 substance is cultured in the medium, and the isolated K04-0144A substance, K04-0144B substance and K04-0144C substance therefrom have strong antibacterial activities against Gram-positive bacteria including methicillin-resistant Streptococcus aureus (MRSA), consequently these are useful as the therapeutic agents for infectious disease caused by MRSA as well as infectious diseases caused by multidrug including β-lactam antibiotics resistant bacteria. Further, similarly, since the novel K04-0144D substance isolated from the cultured liquid has the action for enhancing the effect of β-lactam antibiotics, which are utilized as the antibacterial agents, in combination with them, it is useful as the therapeutic agent for infectious diseases caused by methicillin-resistant Staphylococcus aureus (MRSA) and multidrug including β-lactam antibiotics resistant bacteria.

    摘要翻译： 属于Streptomyces sp。的菌株K04-0144所代表的微生物 在培养基中培养生产K04-0144物质的能力，分离的K04-0144A物质，K04-0144B物质和K04-0144C物质对革兰氏阳性菌（包括耐甲氧西林金黄色葡萄球菌（MRSA））具有很强的抗菌活性， 因此，这些可用作由MRSA引起的感染性疾病的治疗剂以及由多种药物（包括β-内酰胺抗生素抗性细菌）引起的感染性疾病。 此外，类似地，由于从培养液中分离的新型K04-0144D物质具有增强作为抗菌剂的β-内酰胺抗生素与其组合的作用，因此可用作治疗剂 用于由耐甲氧西林金黄色葡萄球菌（MRSA）引起的感染性疾病和包含β-内酰胺抗生素抗性细菌的多药物。

    Novel k99-5278 substance and a process for producing the same
    10.
    发明申请
    Novel k99-5278 substance and a process for producing the same 审中-公开
    新型k99-5278物质及其制备方法

    公开(公告)号：US20060014825A1

    公开(公告)日：2006-01-19

    申请号：US10492654

    申请日：2002-10-11

    申请人： Satoshi Omura ,  Hiroshi Tomoda ,  Yoko Takahashi

    发明人： Satoshi Omura ,  Hiroshi Tomoda ,  Yoko Takahashi

    IPC分类号： A61K31/365 ,  C12P17/02 ,  C07D313/00

    CPC分类号： C07D313/00 ,  C07D315/00 ,  C12P17/08 ,  C12R1/465

    摘要： The present invention relates to effective drugs for mycosis caused by so called fungi such as fungi and yeast. The present invention is comprised of culturing a microorganism belonging to genus Streptomyces and having ability to produce K99-5278A substance, K99-5278B substance and K99-5278C substance in a medium, accumulating K99-5278A substance, K99-5278B substance and K99-5278C substance in the cultured medium and isolating K99-5278A substance, K99-5278B substance and K99-5278C substance from the cultured mass. The thus obtained substances can be expected as a novel antifungal agent.

    摘要翻译： 本发明涉及由所谓的真菌如真菌和酵母引起的用于真菌病的有效药物。 本发明包括培养属于链霉菌属的微生物，并且能够在培养基中生产K99-5278A物质，K99-5278B物质和K99-5278C物质，积累K99-5278A物质，K99-5278B物质和K99-5278C 培养基中的物质，并从培养物质中分离K99-5278A物质，K99-5278B物质和K99-5278C物质。 可以预期由此获得的物质作为新颖的抗真菌剂。